Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study
Summary Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2016-12, Vol.16 (12), p.1364-1376 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1376 |
|---|---|
| container_issue | 12 |
| container_start_page | 1364 |
| container_title | The Lancet infectious diseases |
| container_volume | 16 |
| creator | Aliberti, Stefano, MD Reyes, Luis F, MD Faverio, Paola, MD Sotgiu, Giovanni, MD Dore, Simone, MD Rodriguez, Alejandro H, MD Soni, Nilam J, MD Restrepo, Marcos I, Dr |
| description | Summary Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None. |
| doi_str_mv | 10.1016/S1473-3099(16)30267-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846416003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1473309916302675</els_id><sourcerecordid>1846416003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-235f3f4ae3f0f4a706b68f72e43ffbe8e09aa6f204eb4de6c7cad5ee828d25d93</originalsourceid><addsrcrecordid>eNqNkV2L1DAUhoso7rr6E5SCN7NgNWk-2nqhyKLjwojC6nVI0xM2a5qMSTowd_vTN9OOCnujVycnPOcJJ29RPMfoNUaYv7nCtCEVQV23wvycoJo3FXtQnOZrWlHKmofzeUFOiicx3iCEG4zo4-KkblhHWItPi9u19b20pXEmGZnMDkrtQzlCMspYa1wVIJqYpEvlVZLb6731yis1xVJOAXLZOphG74wsV-vN5Zdv529L6bIvQXBZ6J20r0rfRwi7Y1sqf-1DKmOahv3T4pGWNsKzYz0rfnz6-P3ic7X5ur68-LCpFOtoqmrCNNFUAtEolwbxnre6qYESrXtoAXVScl0jCj0dgKtGyYEBtHU71GzoyFmxWrzb4H9NEJMYTVRgrXTgpyhwSznFHCHyHyhhDBNS84y-vIfe-CnvbWchbnhDyYFiC6WCjzGAFttgRhn2AiNxSFPMaYpDVCJ3c5qC5bkXR_vUjzD8mfodXwbeLwDkn9sZCCIqA07BYAKoJAZv_vnEu3sGlUM3StqfsIf4dxsRa4EWycGB-Wxg5A69YsXi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841767436</pqid></control><display><type>article</type><title>Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Aliberti, Stefano, MD ; Reyes, Luis F, MD ; Faverio, Paola, MD ; Sotgiu, Giovanni, MD ; Dore, Simone, MD ; Rodriguez, Alejandro H, MD ; Soni, Nilam J, MD ; Restrepo, Marcos I, Dr</creator><creatorcontrib>Aliberti, Stefano, MD ; Reyes, Luis F, MD ; Faverio, Paola, MD ; Sotgiu, Giovanni, MD ; Dore, Simone, MD ; Rodriguez, Alejandro H, MD ; Soni, Nilam J, MD ; Restrepo, Marcos I, Dr ; GLIMP investigators</creatorcontrib><description>Summary Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(16)30267-5</identifier><identifier>PMID: 27593581</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Aged ; Antibiotic resistance ; Antibiotics ; Cardiovascular disease ; Chronic obstructive pulmonary disease ; Cohort Studies ; Community-Acquired Infections - epidemiology ; Community-Acquired Infections - microbiology ; Coronary vessels ; Cross Infection ; Drug resistance ; Female ; Global Health ; Hospitals ; Humans ; Infectious Disease ; Infectious diseases ; Male ; Methicillin Resistance ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Methicillin-Resistant Staphylococcus aureus - isolation & purification ; Mortality ; Observational studies ; Ostomy ; Pathogens ; Pneumonia ; Pneumonia - diagnostic imaging ; Pneumonia - epidemiology ; Pneumonia - microbiology ; Prevalence ; Public health ; Regression analysis ; Researchers ; Respiratory tract ; Retrospective Studies ; Risk Factors ; Staphylococcal Infections - epidemiology ; Staphylococcal Infections - microbiology ; Staphylococcus aureus ; Staphylococcus infections ; Studies</subject><ispartof>The Lancet infectious diseases, 2016-12, Vol.16 (12), p.1364-1376</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Dec 01, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-235f3f4ae3f0f4a706b68f72e43ffbe8e09aa6f204eb4de6c7cad5ee828d25d93</citedby><cites>FETCH-LOGICAL-c594t-235f3f4ae3f0f4a706b68f72e43ffbe8e09aa6f204eb4de6c7cad5ee828d25d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309916302675$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27593581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aliberti, Stefano, MD</creatorcontrib><creatorcontrib>Reyes, Luis F, MD</creatorcontrib><creatorcontrib>Faverio, Paola, MD</creatorcontrib><creatorcontrib>Sotgiu, Giovanni, MD</creatorcontrib><creatorcontrib>Dore, Simone, MD</creatorcontrib><creatorcontrib>Rodriguez, Alejandro H, MD</creatorcontrib><creatorcontrib>Soni, Nilam J, MD</creatorcontrib><creatorcontrib>Restrepo, Marcos I, Dr</creatorcontrib><creatorcontrib>GLIMP investigators</creatorcontrib><title>Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.</description><subject>Aged</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Cardiovascular disease</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cohort Studies</subject><subject>Community-Acquired Infections - epidemiology</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Coronary vessels</subject><subject>Cross Infection</subject><subject>Drug resistance</subject><subject>Female</subject><subject>Global Health</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Methicillin Resistance</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Methicillin-Resistant Staphylococcus aureus - isolation & purification</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Ostomy</subject><subject>Pathogens</subject><subject>Pneumonia</subject><subject>Pneumonia - diagnostic imaging</subject><subject>Pneumonia - epidemiology</subject><subject>Pneumonia - microbiology</subject><subject>Prevalence</subject><subject>Public health</subject><subject>Regression analysis</subject><subject>Researchers</subject><subject>Respiratory tract</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Staphylococcal Infections - epidemiology</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus infections</subject><subject>Studies</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkV2L1DAUhoso7rr6E5SCN7NgNWk-2nqhyKLjwojC6nVI0xM2a5qMSTowd_vTN9OOCnujVycnPOcJJ29RPMfoNUaYv7nCtCEVQV23wvycoJo3FXtQnOZrWlHKmofzeUFOiicx3iCEG4zo4-KkblhHWItPi9u19b20pXEmGZnMDkrtQzlCMspYa1wVIJqYpEvlVZLb6731yis1xVJOAXLZOphG74wsV-vN5Zdv529L6bIvQXBZ6J20r0rfRwi7Y1sqf-1DKmOahv3T4pGWNsKzYz0rfnz6-P3ic7X5ur68-LCpFOtoqmrCNNFUAtEolwbxnre6qYESrXtoAXVScl0jCj0dgKtGyYEBtHU71GzoyFmxWrzb4H9NEJMYTVRgrXTgpyhwSznFHCHyHyhhDBNS84y-vIfe-CnvbWchbnhDyYFiC6WCjzGAFttgRhn2AiNxSFPMaYpDVCJ3c5qC5bkXR_vUjzD8mfodXwbeLwDkn9sZCCIqA07BYAKoJAZv_vnEu3sGlUM3StqfsIf4dxsRa4EWycGB-Wxg5A69YsXi</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Aliberti, Stefano, MD</creator><creator>Reyes, Luis F, MD</creator><creator>Faverio, Paola, MD</creator><creator>Sotgiu, Giovanni, MD</creator><creator>Dore, Simone, MD</creator><creator>Rodriguez, Alejandro H, MD</creator><creator>Soni, Nilam J, MD</creator><creator>Restrepo, Marcos I, Dr</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study</title><author>Aliberti, Stefano, MD ; Reyes, Luis F, MD ; Faverio, Paola, MD ; Sotgiu, Giovanni, MD ; Dore, Simone, MD ; Rodriguez, Alejandro H, MD ; Soni, Nilam J, MD ; Restrepo, Marcos I, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-235f3f4ae3f0f4a706b68f72e43ffbe8e09aa6f204eb4de6c7cad5ee828d25d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Cardiovascular disease</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cohort Studies</topic><topic>Community-Acquired Infections - epidemiology</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Coronary vessels</topic><topic>Cross Infection</topic><topic>Drug resistance</topic><topic>Female</topic><topic>Global Health</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Methicillin Resistance</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Methicillin-Resistant Staphylococcus aureus - isolation & purification</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Ostomy</topic><topic>Pathogens</topic><topic>Pneumonia</topic><topic>Pneumonia - diagnostic imaging</topic><topic>Pneumonia - epidemiology</topic><topic>Pneumonia - microbiology</topic><topic>Prevalence</topic><topic>Public health</topic><topic>Regression analysis</topic><topic>Researchers</topic><topic>Respiratory tract</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Staphylococcal Infections - epidemiology</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus infections</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aliberti, Stefano, MD</creatorcontrib><creatorcontrib>Reyes, Luis F, MD</creatorcontrib><creatorcontrib>Faverio, Paola, MD</creatorcontrib><creatorcontrib>Sotgiu, Giovanni, MD</creatorcontrib><creatorcontrib>Dore, Simone, MD</creatorcontrib><creatorcontrib>Rodriguez, Alejandro H, MD</creatorcontrib><creatorcontrib>Soni, Nilam J, MD</creatorcontrib><creatorcontrib>Restrepo, Marcos I, Dr</creatorcontrib><creatorcontrib>GLIMP investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aliberti, Stefano, MD</au><au>Reyes, Luis F, MD</au><au>Faverio, Paola, MD</au><au>Sotgiu, Giovanni, MD</au><au>Dore, Simone, MD</au><au>Rodriguez, Alejandro H, MD</au><au>Soni, Nilam J, MD</au><au>Restrepo, Marcos I, Dr</au><aucorp>GLIMP investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>16</volume><issue>12</issue><spage>1364</spage><epage>1376</epage><pages>1364-1376</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>27593581</pmid><doi>10.1016/S1473-3099(16)30267-5</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2016-12, Vol.16 (12), p.1364-1376 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1846416003 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Antibiotic resistance Antibiotics Cardiovascular disease Chronic obstructive pulmonary disease Cohort Studies Community-Acquired Infections - epidemiology Community-Acquired Infections - microbiology Coronary vessels Cross Infection Drug resistance Female Global Health Hospitals Humans Infectious Disease Infectious diseases Male Methicillin Resistance Methicillin-Resistant Staphylococcus aureus - drug effects Methicillin-Resistant Staphylococcus aureus - isolation & purification Mortality Observational studies Ostomy Pathogens Pneumonia Pneumonia - diagnostic imaging Pneumonia - epidemiology Pneumonia - microbiology Prevalence Public health Regression analysis Researchers Respiratory tract Retrospective Studies Risk Factors Staphylococcal Infections - epidemiology Staphylococcal Infections - microbiology Staphylococcus aureus Staphylococcus infections Studies |
| title | Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T17%3A05%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Global%20initiative%20for%20meticillin-resistant%20Staphylococcus%20aureus%20pneumonia%20(GLIMP):%20an%20international,%20observational%20cohort%20study&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Aliberti,%20Stefano,%20MD&rft.aucorp=GLIMP%20investigators&rft.date=2016-12-01&rft.volume=16&rft.issue=12&rft.spage=1364&rft.epage=1376&rft.pages=1364-1376&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(16)30267-5&rft_dat=%3Cproquest_cross%3E1846416003%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841767436&rft_id=info:pmid/27593581&rft_els_id=1_s2_0_S1473309916302675&rfr_iscdi=true |